Taking stock of the drug industry, from the lab to the medicine chestOctober 9, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Novo Nordisk to buy Akero Therapeutics, picking up promising MASH drug The deal, worth $4.7 billion upfront, centers on the drug efruxifermin, which has shown promising results in trials. By Adam Feuerstein STAT+ | The limits of FDA flexibility are tested as a controversial Biohaven drug decision nears With treatments for rare diseases, clinical data may not matter as much to FDA officials as they do in other cases. By Adam Feuerstein STAT+ | Monopar resurrects a shelved Wilson disease drug. Spotting a possible math problem helped The therapy was abandoned by AstraZeneca, but a co-inventor believed the company had made a formula error in analyzing data. By Adam Feuerstein Brooke Alexander for STAT STAT+ | Expedition Therapeutics, a biotech company scouring China for drug candidates, raises $165 million The funding will be used to advance a drug for the lung condition COPD that was originally developed by Shanghai drugmaker Fosun Pharma. By Allison DeAngelis Opinion: Pharma's shift away from infectious disease research could spell disaster for the world's poorest people Fundamental changes to pharma are destroying the model that let my nonprofit bring medicine to the Global South. By Laurent Fraisse More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments